Anti-CCRL2 antibody

• Flow Cyt

Unknown

Flow Cytometry - Anti-CCRL2 antibody (AB88632)

FACS analysis of negative control 293 cells (black) and CCRL2-expressing 293 cells (green) using ab88632.

• WB

Unknown

Western blot - Anti-CCRL2 antibody (AB88632)

All lanes:

Western blot - Anti-CCRL2 antibody (ab88632) at 1 µg/mL

Lane 1:

CCRL2-transfected 293T cell lysate at 25 µg

Lane 2:

Non-transfected 293T cell lysate at 25 µg

Predicted band size: 40 kDa

Observed band size: 38 kDa

false

• WB

Unknown

Western blot - Anti-CCRL2 antibody (AB88632)

All lanes:

Western blot - Anti-CCRL2 antibody (ab88632) at 1 µg/mL

All lanes:

Raw 264.7 cell lysate at 50 µg

Predicted band size: 40 kDa

false

• WB

Unknown

Western blot - Anti-CCRL2 antibody (AB88632)

All lanes:

Western blot - Anti-CCRL2 antibody (ab88632) at 1 µg/mL

All lanes:

NIH/3T3 cell lysate at 50 µg

Predicted band size: 40 kDa

false

• WB

CiteAb

Western blot - Anti-CCRL2 antibody (AB88632)

CCRL2 western blot using anti-CCRL2 antibody ab88632. Publication image and figure legend from Zhang, Y., Li, S., et al., 2020, Inflammation, PubMed 31748849.

ab88632 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab88632 please see the product overview.

The silencing of CCRL2/CX3CR1 abrogates the MTB Hsp16.3-induced polarization of macrophages to the M2 phenotype. Bone marrow cells were isolated from the tibias and femurs of BALB/c mice (6–8 weeks old) and incubated with 20 ng/ml GM-CSF for 7 days. Then, BMDMs were transfected with siRNA targeting CCRL2 and CX3CR1. a mRNA expression levels of CCRL2 and CX3CR1 were measured by real-time PCR after transfection. b Western blot analysis of CCRL2 and CX3CR1 in the untreated BMDM group and +Hsp16.3 BMDM group transfected with siRNA targeting mouse CCRL2 and CX3CR1 for 0–48 h. c Real-time PCR analysis of mRNA expression levels of Arg-1, IL-10, TGF-β, and YM-1 in untreated BMDMs and Hsp16.3-treated BMDMs transfected with siRNA targeting mouse CCRL2 and CX3CR1 for 0–72 h. d FCM analysis of the expression levels of NOS2 and CD206 in the untreated BMDM group and +Hsp16.3 BMDM group transfected with siRNA targeting mouse CCRL2 and CX3CR1 for 0–48 h. e ELISA analysis of the secretion levels of IL-10, TGF-β, and TNF-α in the untreated BMDM group and +Hsp16.3 BMDM group transfected with siRNA targeting mouse CCRL2 or CX3CR1 for 48 h. f Western blot analysis of p-ERK, ERK, p-AKT, AKT, p-p-38 MAPK, p-38 MAPK in the +Hsp16.3 BMDM group, and +Hsp16.3 BMDM group transfected with siRNA targeting mouse CCRL2 or CX3CR1 at different time points. Data are presented as the mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control group (0 h group).

false